Last
Update:
April 20, 2018
 Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
-
A Trial of a Single Tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine,
and Tenofovir Disoproxil Fumarate for the Initial Treatment of HIV-2
Infection in a Resource-Limited Setting: 48 Week Results from Senegal, West
Africa.
Ba S, Raugi DN, Smith RA, et al
Clin Infect Dis.
2018 Apr 17
Abstract
-
HIV integrase inhibitor, Elvitegravir, impairs RAG functions and inhibits V(D)J
recombination.
Nishana M, Nilavar NM, Kumari R,
et al
Cell Death Dis. 2017 Jun 1
Abstract
-
Elvitegravir concentrations in seminal plasma in HIV-1-infected
men.
Imaz A, Niubó J, Kashuba AD,
et al
HIV
Med. 2016 Aug 1
Abstract
-
Impact of elvitegravir on human adipocytes: Alterations in differentiation, gene
expression and release of adipokines and cytokines.
Moure
R, Domingo P, Gallego-Escuredo JM. et al
Antiviral Res. 2016 May 20.
Abstract
-
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A
Review in HIV-1 Infection.
Greig SL, Deeks ED.
Drugs. 2016 May 17
Abstract
-
Pharmacokinetic profile of raltegravir, elvitegravir and
dolutegravir in plasma and mucosal secretions in rhesus macaques.
Massud I, Martin A, Dinh C, Mitchell J, et al
GAntimicrob Chemother.
2015 Jan 27.
Abstract
-
Critical appraisal of elvitegravir in the treatment of
HIV-1/AIDS.
Pandey KK.
HIV AIDS
(Auckl).
2014 May 16;6:81-90.
Abstract
-
Elvitegravir: A Review of Its Use in Adults with HIV-1 Infection.
Deeks ED.
Drugs.
2014 Mar 27
Abstract
-
Examining structural analogs of elvitegravir as
potential inhibitors of HIV-1 integrase.
Shah K, Gupta S, Mishra H, et al
Arch Virol. 2014 Mar 19
Abstract
-
The elvitegravir Quad pill: the first once-daily
dual-target anti-HIV tablet.
Marchand C.|
Expert Opin Investig Drugs.
2012 May 10
Paper
-
Elvitegravir : a once-daily inhibitor of HIV-1
integrase.
Wills T, Vega V.
Expert Opin Investig Drugs.
2012 Feb 10
Abstract
-
Elvitegravir: a new HIV integrase inhibitor.
Shimura K, Kodama EN.
Antivir Chem Chemother.
2009 Oct 19;20(2):79-85
Abstract
-
FULL-TEXT PDF ARTICLE
Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1
integrase inhibitors.
Serrao E, Odde S, Ramkumar K, Neamati N.
Retrovirology.
2009 Mar 5;6(1):25.
Paper
-
Correction: Raltegravir, elvitegravir, and metoogravir: the
birth of "me-too" HIV-1 integrase inhibitors.
Serrao E, Odde S, Ramkumar K, Neamati N.
Retrovirology. 2009
Apr 8;6(1):33.
Abstract
-
Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and
elvitegravir phenotypic susceptibility.
Van Baelen K, Van Eygen V, Rondelez E, Stuyver LJ.
AIDS. 2008 Sep 12;22(14):1877-80
Abstract
-
HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2
clinical isolates to the integrase inhibitors
raltegravir and elvitegravir in vitro.
Roquebert B, Damond F, Collin G, et al
J Antimicrob Chemother. 2008 Aug 20.
Abstract
-
Broad Anti-Retroviral Activity and Resistance Profile of a Novel
Human Immunodeficiency Virus
Integrase Inhibitor, Elvitegravir (JTK-303/GS-9137).
Shimura K, Kodama E, Sakagami Y
Virol. 2007 Oct 31;
Abstract
-
Antiviral Activity, Pharmacokinetics, and Dose Response of the HIV-1
Integrase Inhibitor GS-9137
(JTK-303) in Treatment-Naive and Treatment-Experienced Patients.
Dejesus E, Berger D, Markowitz M ,et al
J Acquir Immune Defic Syndr.
2006 Sep;43(1):1-5.
Abstract
|
-
FULL-TEXT ARTICLE
Alterations in cellular pharmacokinetics and pharmacodynamics of
elvitegravir in response to ethanol exposure in HIV-1 infected
monocytic (U1) cells.
Midde NM, Sinha N, Lukka PB, et
al
PLoS One.
2017 Feb 23;12(2):e0172628
Paper-
Population pharmacokinetic analysis of elvitegravir
and cobicistat in HIV-1-infected individuals.
Barceló C, Gaspar F, Aouri M, Panchaud
A, ert al
J Antimicrob Chemother.
2016 Mar 29.
Abstract
Pharmacokinetics and Safety of Boosted-Elvitegravir in Subjects with
Hepatic Impairment
Custodio JM,
Rhee M,
Shen G,
et al
Antimicrob. Agents Chemother.
18
February 2014,
Abstract
-
Pharmacokinetics of cobicistat boosted-elvitegravir
administered in combination with rosuvastatin.
Custodio JM, Wang H, Hao J, et al
J Clin Pharmacol.
2013 Dec 28
Abstract
-
Pharmacokinetics of once-daily boosted elvitegravir
when administered in combination with Acid-reducing agents.
Ramanathan S, Mathias A, Wei X,
J Acquir Immune Defic Syndr. 2013
Sep 1;64(1):45-50.
Abstract
-
Effects of Etravirine on the Pharmacokinetics of the Integrase
Inhibitor S/GSK1265744.
Ford SL, Gould E, Chen S,
et al
Antimicrob Agents Chemother.
2012 Oct 31.
Abstract
-
Clinical Pharmacokinetic and Pharmacodynamic Profile of
the HIV Integrase Inhibitor
Elvitegravir.
Ramanathan S, Mathias AA, German P, Kearney BP
Clin Pharmacokinet.
2011 Apr 1;50(4):229-44
Abstract
-
Pharmacokinetics and bioavailability of an integrase
and novel pharmacoenhancer-containing single-tablet
fixed-dose
combination regimen for the treatment of HIV.
German P, Warren D, West S, et al
J Acquir Immune Defic Syndr.
2010 Nov 1;55(3):323-9.
Abstract
-
Pharmacokinetic interaction of ritonavir-boosted
elvitegravir and maraviroc.
Ramanathan S,
Abel S, Tweedy S,
et al
J Acquir Immune Defic Syndr.
2010 Feb 1;53(2):209-14.
Abstract'
-
Pharmacokinetics and Pharmacodynamics of GS-9350: A Novel
Pharmacokinetic Enhancer
Without Anti-HIV Activity.
Mathias AA, German P, Murray BP, et al
Clin Pharmacol Ther.
2009 Dec 30.
Abstract
-
Effect of Ritonavir-Boosted Tipranavir or Darunavir on the
Steady-State Pharmacokinetics of Elvitegravir.
Mathias AA, Hinkle J, Shen G,., et al
J Acquir Immune Defic Syndr. 2008 Sep 2.
Abstract'
-
Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following
coadministration of emtricitabine/tenofovir disoproxil
fumarate and ritonavir-boosted GS-9137.
Ramanathan S, Shen G, Cheng A, Kearney BP.
J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):274-9.
Abstract'
-
Pharmacokinetics of Coadministered Ritonavir-Boosted Elvitegravir
and Zidovudine, Didanosine,
Stavudine, or Abacavir.
Ramanathan S, Shen G, Hinkle J, et alJ
Acquir Immune Defic Syndr. 2007 Aug 9;
Abstract'
|
-
Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on
raltegravir: a French national study of raltegravir-experienced HIV-1-infected
patients.
Fourati S, Charpentier C, Amiel C,
et al
J Antimicrob Chemother. 2015 Jan 3. pii:
dku535
Abstract
-
Molecular dynamics simulation studies of the wild type and
E92Q/N155H mutant of Elvitegravir-resistance HIV-1 integrase
Chen Q, Cheng X, Wei D, Xu Q.
Interdiscip Sci. 2014 Nov 6.
Abstract
-
Raltegravir and elvitegravir-resistance mutation E92Q affects HLA-B*40:02-restricted
HIV-1-specific CTL recognition.
Rahman MA, Kuse N, Murakoshi H, et al
Microbes Infect. 2014
Mar 20.
Abstract
-
In vitro phenotypes to elvitegravir and dolutegravir in
primary macrophages and lymphocytes of clonal recombinant viral
variants selected in patients failing raltegravir.
Canducci F, Ceresola ER, Saita D, et al
J Antimicrob Chemother.
2013 Jun 24.
Abstract
-
Multiple Genetic Pathways Involving Amino Acid Position
143 of HIV-1 Integrase Are Preferentially Associated with Specific
Secondary Amino Acid Substitutions and Confer Resistance to
Raltegravir and Cross-Resistance to Elvitegravir.
Huang W, Frantzell A,
Fransen S, Petropoulos CJ.
Antimicrob Agents Chemother.
2013 Jun 3
Abstract'
-
Impact of Primary Elvitegravir Resistance-Associated
Mutations in HIV-1 Integrase on Drug Susceptibility and Viral
Replication Fitness.
Abram ME, Hluhanich RM, Goodman DD, et al
A
Antimicrob Agents Chemother.
2013 Mar 25
Abstract'
-
FULL-TEXT
ARTICLE
Development of elvitegravir resistance and linkage of integrase
inhibitor mutations with protease and reverse transcriptase resistance
mutations.
Winters MA, Lloyd RM Jr, Shafer RW,
et al
PLoS One. 2012;7(7):e40514.
Paper
-
Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected
Patients Failing on
Raltegravir-Containing Regimens.
Garrido C, Villacian J, Zahonero N, et al
Antimicrob Agents Chemother.
2012 Mar 26
Abstract
-
In vitro resistance selections using elvitegravir, raltegravir, and
two metabolites of elvitegravir
M1 and M4.
Margot NA, Hluhanich RM, Jones GS,
et al
Antiviral Res. 2011 Dec
16.
Abstract
-
Cross-resistance profile determination of two second-generation HIV-1
integrase inhibitors using a panel of
recombinant viruses derived from raltegravir-treated clinical
isolates.
Van Wesenbeeck L, Rondelez E, Feyaerts M, et al
Antimicrob Agents Chemother.
2011 Jan;55(1):321-
Abstract
-
Identification of novel mutations responsible for
resistance to MK-2048, a second-generation HIV-1 integrase inhibitor.
Bar-Magen T, Sloan RD, Donahue DA,
et al
J Virol. 2010
Sep;84(18):9210-6.
Abstract
-
Genetic barriers for integrase inhibitor drug
resistance in HIV type-1 B and CRF02_AG subtypes.
Maïga AI, Malet I, Soulie C,
et al
Antivir Ther. 2009;14(1):123-
Abstract
-
Comparison of Raltegravir and Elvitegravir on HIV-1 Integrase Catalytic
Reactions and on a Series of
Drug-Resistant Integrase Mutants.
Marinello J, Marchand C, Mott BT, et al
Biochemistry. 2008 Sep 9;47(36):9345-9354
Abstract
-
Resistance mutations in HIV-1 integrase selected with Elvitegravir confer
reduced susceptibility to a wide range of
integrase inhibitors.
Goethals O, Clayton R, Van Ginderen M, et al
J Virol. 2008 Aug 20.
Abstract
-
FULL-TEXT ARTICLE
Broad antiretroviral activity and resistance profile of the novel human
immunodeficiency virus integrase inhibitor
elvitegravir (JTK-303/GS-9137).
Shimura K, Kodama E, Sakagami, et al
J Virol. 2008 Jan;82(2):764-74.
Paper
-
Genetic diversity of integrase (IN) sequences in
antiretroviral treatment-naive and treatment-experienced HIV
type 2 patients.
Xu L, Anderson J, Ferns B, et al
AIDS Res Hum Retroviruses. 2008 Jul;24(7):1003-7.
Abstract
-
Mutations in human immunodeficiency virus type 1 integrase
confer resistance to the naphthyridine L-870,810 and
cross-resistance to the clinical trial drug GS-9137.
Hombrouck A, Voet A, Van Remoortel B, et al
Antimicrob Agents Chemother. 2008 Jun;52(6):2069-78.
Abstract
-
Comparison of Raltegravir and Elvitegravir on HIV-1 Integrase Catalytic
Reactions and on a Series of Drug-Resistant Integrase Mutants.
Marinello J, Marchand C, Mott BT, et al
Biochemistry. 2008 Aug 15.
Abstract
|
|
|
|
General
Studies
Elvitegravir
Main Page